Lumiradx receives uk ctda approval for covid ultra and covid & rsv tests

London, june 20, 2023 (globe newswire) -- lumiradx limited (nasdaq: lmdx) today announced that it has received validation for use by the mhra under the ctda process for the lumiradx sars-cov-2 ag ultra and lumiradx sars-cov2 ag & rsv tests. this milestone supports the uk in preparing for the upcoming respiratory season with tests that allow for rapid detection of sars-cov-2 infection as well as helping to differentiate between sars-cov-2 and rsv when respiratory symptoms are present.
LMDX Ratings Summary
LMDX Quant Ranking